Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

That flexibility, in addition to a quick turnaround and the end product, makes digital art appealing from a commercial perspective. Of course, the tablets, styluses, and pads can cost quite a bit.

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the pharmaceutical company from preparing for its launch.

(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in ...

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen reports. One participant lost 22% of her weight ...

Eli Lilly continues to ... quarter to $1.3 billion. However, Lilly saw strength in other drugs as well, with overall non-incretin revenue growing 20%. Verzenio, which is used to treat HR+, HER2 ...

Before they hit airwaves, however, Eli Lilly dropped a breast ... than a promo for breast cancer med Verzenio or any of its other cancer drugs, Lilly is hoping to raise “awareness and trust ...

Eli Lilly's existing portfolio, excluding incretins, also has potential growth contributors. The pharmaceutical company is expected to benefit from blockbuster products like Verzenio in oncology, ...

Eli Lilly's existing portfolio, excluding incretins, also has potential growth contributors. The pharmaceutical company is expected to benefit from blockbuster products like Verzenio in oncology ...